Published in Hepatitis Weekly, October 9th, 2006
Study 1: A study from South Korea has reported on the increased risk of adefovir resistance in patients with lamivudine (LAM)-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil (ADV) monotherapy.
"Although ADV has a unique profile of delayed and infrequent resistance in treatment-naive chronic hepatitis B patients, the association of ADV resistance with previous LAM resistance is not well understood.
"We compared the emergence of the ADV-resistant mutations rtA181V/T and rtN236T between LAM-resistant patients and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.